Business Context and Reporting Period
Company: ANAVEX LIFE SCIENCES CORP.
Filing Type: Form 8-K (Current Report)
Date of Report: July 5, 2010
Principal Office: Athens, Greece
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific capital transaction.
| Transaction Detail | Value/Description |
|---|---|
| Securities Issued | 400,000 Units |
| Deemed Value per Unit | US $2.50 |
| Total Deemed Value | US $1,000,000 |
| Unit Composition | 1 Common Share + 0.5 Warrant |
| Warrant Exercise Price | US $3.50 per share |
| Warrant Term | 18 months |
Material Changes
The primary material change is the issuance of 400,000 units to Eurogenet Labs SA under a "shares for services" agreement dated July 5, 2010. This transaction was conducted outside the United States with a non-U.S. person, relying on exemptions under Regulation S and Section 4(2) of the Securities Act of 1933.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, outlook, or general management commentary regarding future operations or financial projections.
Risks and Contingencies: The filing notes the reliance on specific registration exemptions for the offshore transaction. No other material risks or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the nature and valuation of services provided by Eurogenet Labs SA to justify the $1,000,000 deemed value.
- Confirm the dilution impact of the 400,000 new shares and associated warrants on existing shareholders.
- Review the full "Shares for Services Agreement" (Exhibit 10.1) for specific performance milestones or obligations.
- Check subsequent filings for any financial impact of this non-cash transaction on the company's balance sheet.